Ariosa Diagnostics is fighting to revoke a patent for noninvasive prenatal test owned by Sequenom, arguing it merely describes how to extract “incorporeal” genetic information that is naturally found within the DNA of an unborn foetus.
Drug maker Janssen has fired off a lawsuit against Juno Pharmaceuticals for allegedly threatening to infringe a patent for its HIV drug Prezista with a generic version of the drug, one year after fending off generic competition from a different drug maker.
In a defeat to the Australian Securities and Investments Commission, a judge has found a key witness in the trial against former Quintis director Frank Wilson must give evidence in person, delaying the hearing indefinitely until coronavirus-related travel restrictions are lifted.
Medical technology company Respiri has settled a lawsuit brought by its former CEO alleging he was terminated for seeking to expand into the Indian market against the wishes of the ASX-listed company’s board.
An employee from not-for-profit aged care health provider Ozcare who claims the company discriminated against her through its mandatory flu vaccine policies has had her case thrown out of the Fair Work Commission.
Animal health company Abbey Laboratories has successfully challenged an application by rival Bayer Australia for a patent covering a treatment for biting lice.
A penalty hearing in the ACCC’s case against health booking company HealthEngine over misleading online reviews has been adjourned after a judge criticised the parties’ joint submissions as “deficient” for failing to explain how a proposed $2.9 million penalty had been arrived at.
The former CEO and director of biotech company Sirtex Medical was sentenced Thursday to 18 months’ imprisonment for insider trading but was released immediately on a three-year good behaviour bond.
AFT Pharmaceuticals is seeking to reopen a lawsuit against Reckitt Benckiser over ads for its painkiller Maxigesic after judgment was delivered in the matter, claiming the judge’s declarations contained an error, an argument slammed by Reckitt as “extraordinary”.
Medical device giant Johnson & Johnson has confirmed it will not seek the recusal of a Federal Court judge from a panel overseeing its pelvic mesh class action appeal, despite earlier raising concerns that he had seen privileged settlement communications.